ABEO

Abeona Therapeutics

Fundamental data last updated:March 2, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

18 Days

Business Summary

Abeona Therapeutics is a clinical-stage biopharmaceutical company. It focuses on developing gene and cell therapies for serious and life-threatening rare genetic diseases.

VALUATION

P/E

4.2

Market Cap ($M USD)

$277

Forward P/E

-

PEG

-

PRICE TO SALES

500+

PRICE TO BOOK

1.6

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$1.62

Next Year EPS Growth Estimate

-$0.07

Next Year Revenue Growth Estimate

1766.70%

Return on Equity (ROE)

48.10%

Operating Margin

-20802.20%

Debt-to-Equity

0.1

Gainseekers Quantitative Analysis

Summary

Abeona Therapeutics has a market capitalization of $277 million and a Price / Earnings ratio of 4.2, with a current EPS of $1.62. The company exhibits an extremely negative Operating Margin of -20802.20% and a high Price / Sales ratio of over 500. While institutional ownership is high at 73.00%, estimated EPS for next year is negative at -$0.07.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding the company's AI exposure or technological reliance.

The Bull Case

The company shows a strong Return on Equity of 48.10% and a very low Debt / Equity ratio of 0.1. Analysts have a consensus rating of 1 and a mean target price of $20.64, supported by an estimated sales growth of 1766.70% for next year.

The Bear Case

The company's extremely negative Operating Margin of -20802.20% and a Price / Sales ratio over 500 indicate significant operational and valuation concerns. This is compounded by a high Short % of Float at 28.20% and a negative EPS estimate of -$0.07 for the upcoming year.

Market Sentiment & Smart Money

Short Interest %

28.20%

Analyst Consensus

1

Average Analyst Price Target

$20.64

Institutional Ownership %

73.00%